Glucagon-like peptide 1 receptor agonist prescription linked to reduction in risk for suicidal ideation or attempts<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Oct. 15, 2024 (HealthDay News) — For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to a study published online Oct. 14 in JAMA Pediatrics<\/em>.<\/p>\n Liya Kerem, M.D., and Joshua Stokar, M.D., from Hadassah University Medical Center in Israel, examined the incidence of suicidal ideation or attempts following initial prescription of GLP1-RA (study cohort) or a lifestyle intervention without GLP1-RA treatment (control cohort) in a retrospective propensity score-matched cohort. Participants were adolescents aged 12 to 18 years with a diagnosis of obesity and evidence of an antiobesity GLP1-RA prescription or lifestyle intervention without GLP1-RA treatment; after propensity score matching, 3,456 participants were included in each cohort.<\/p>\n The researchers found that the study cohort had a significantly lower risk for suicidal ideation or attempts during 12 months of follow-up (1.45 versus 2.26 percent; hazard ratio, 0.67) and a significantly higher rate of gastrointestinal symptoms, used as a positive control outcome (6.9 versus 5.4 percent; hazard ratio, 1.41). There was no difference between the groups in the rates of upper respiratory tract infection diagnoses, used as a negative control outcome.<\/p>\n “Future prospective studies should assess the association of GLP1-RA treatment with psychiatric outcomes in adolescents with obesity,” the authors write.<\/p>\n One author disclosed ties to Novo Nordisk.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n